Sentiment Summary
Recent Events
Ex-dividend date for the final dividend of RMB 1.43 per share for the fiscal year 2025 on 2026-06-16, scheduled.
Annual General Meeting to be held on 2026-05-21 to review reports and approve plans; routine meetings typically have a 1-5% price impact, scheduled
An earnings briefing for the 2025 fiscal year and Q1 2026 results is scheduled for May 14, 2026. This routine communication event is estimated to have a price impact of at least 1% scheduled.
Caris Life Sciences to report first quarter 2026 financial results on May 7, 2026, scheduled.
Guardant Health is scheduled to release its Q1 2026 financial results after market close on May 7, 2026. Analysts forecast EPS of ($0.47) and revenue of $279.17 million. High importance estimated due to potential for significant volatility following earnings results, scheduled.
Natera is scheduled to release its first quarter 2026 financial results after the market closes on May 7, 2026, with analysts forecasting revenue of approximately $617.5 million and an EPS of -$0.55; high importance is expected due to typical earnings volatility, scheduled.
10x Genomics is scheduled to report its financial results for the first quarter of 2026 after market close on May 7, 2026, followed by a conference call; analysts forecast earnings of ($0.25) per share. High importance is estimated as earnings releases often trigger >10% price movement forecasted scheduled
First quarter 2026 financial results are scheduled to be released on 2026-05-07. Analysts forecast EPS of approximately -$0.17 and revenue of around $39.98 million. Estimated price impact is Medium (5-10%) as earnings reports are key volatility drivers for this stock. scheduled
First Quarter 2026 financial results scheduled to be released after market close. Given the major stock reaction to the last earnings report, this is estimated to be of high importance scheduled
Myriad Genetics is scheduled to release its first quarter 2026 financial results after the market closes on May 5, 2026, with a conference call to follow; high importance is estimated as earnings releases typically trigger price impacts of 10% or more, scheduled.
Veracyte is scheduled to release its financial results for the first quarter of 2026 after the market close on Tuesday, May 5, 2026; high importance is estimated due to potential 10% price impact, which is expected.
Twist Bioscience is scheduled to report its fiscal second quarter 2026 financial results on May 4, 2026, scheduled. High importance is estimated based on the potential for significant price movement typical of earnings announcements in the biotech sector.
GeneDx Holdings Corp. is scheduled to release its financial results for the first quarter of 2026 after the market closes on May 4, 2026. Analysts forecast earnings of ($0.06) per share and revenue of $112.45 million. This event is expected to cause a price impact of at least 5% based on historical volatility, scheduled.
Illumina reported Q1 2026 revenue of $1.09 billion and non-GAAP EPS of $1.15, beating analyst estimates and raising full-year guidance; high impact (>10%) estimated due to strong clinical demand and NovaSeq X placements expected.
Signed a strategic cooperation agreement with DingTalk (an Alibaba company) to upgrade its operations with artificial intelligence applications. This operational partnership is estimated to have a low market impact (≥1%).
Guardant Health announced a multi-year strategic collaboration with Nuvalent on April 30, 2026, to use Guardant's Infinity platform for oncology pipeline development.
Released Q1 2026 earnings on 2026-04-29, reporting a net profit of CNY 1.837 billion (turnaround) and 143.8% revenue growth; high importance due to expected >=10% price impact from significant financial recovery.
The company announced its subsidiary completed a public tender offer on 2026-04-29, acquiring a 67.87% controlling stake in Vietnam-listed Imexpharm Corporation for approximately RMB 1.562 billion, deepening its presence in the Vietnam pharmaceutical market.
Announced that the resubmitted New Drug Application (NDA) for Rademikibart was accepted by China's NMPA on April 29, 2026. Medium importance as NDA acceptance is a key regulatory milestone likely causing >5% price impact.
Announced Q1 2026 results on 2026-04-29: Net profit surged 479.7% YoY to RMB 238 million, primarily due to gains from the fair value change of biological assets, while revenue increased 10% YoY to RMB 316 million. Medium importance is estimated as the profit surge is primarily driven by non-cash fair value changes, likely resulting in a 5-10% price impact. expected
Ex-dividend date for the 2025 final cash dividend of RMB 2 per 10 shares on April 29, 2026; approved at the AGM on April 16, 2026. The dividend amount suggests a >=1% price impact scheduled.
Announced Q1 2026 product revenue exceeded RMB 3.8 billion, a year-over-year increase of over 50%, driven by strong performance of its oncology and general biomedicine portfolios. The stock rose over 4.5% on the news.
Received two clinical trial approvals from China's NMPA for its self-developed Class 1 innovative drug, HS-10522 tablets, for the treatment of uncontrolled hypertension and primary aldosteronism.
The B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 was granted Breakthrough Therapy Designation by China's NMPA for the treatment of advanced castration-resistant prostate cancer.
Announced a 2026 Restricted A-Share Incentive Scheme on 2026-04-29 for directors and supervisors of its subsidiaries, to be funded by existing treasury A-shares and subject to shareholder approval. Low importance is estimated as the scheme involves existing shares and typically results in a price impact between 1% and 5%. scheduled
Announced Q1 2026 results on April 28, 2026, with revenue of RMB 10.07 billion (+6.93% YoY) and net profit attributable to shareholders of RMB 871 million (+13.87% YoY). The 13.87% profit growth is estimated to result in a price impact of at least 10% expected.
Q1 2026 earnings release: revenue CNY 1.801 billion (+15.17% YoY), net profit CNY 49.04 million (-70.36% YoY); the 70% profit drop is estimated to cause a >10% price impact expected.
China's CDE proposed including IBI363, a first-in-class PD-1/IL-2α bispecific antibody, for breakthrough therapy designation for the treatment of advanced MSS/pMMR colorectal cancer. This regulatory progress is estimated to have a medium market impact (≥5%).
Released Q1 2026 earnings on 2026-04-28, with revenue up 15.5% YoY to RMB 3.58 billion and net profit up 9.75% YoY; strong order growth justifies an estimated 5% price impact.
On 2026-04-28, InnoCare announced the first patient has been dosed in its Phase III registrational clinical trial for Orelabrutinib for the treatment of systemic lupus erythematosus (SLE). This clinical milestone is estimated to have a ~5% price impact as it advances a key pipeline asset.
Stock price declined approximately 5% on April 28, 2026, after the FDA released briefing documents expressing concerns about the trial design for AstraZeneca's camizestrant, which uses Guardant's G360 test.
On April 28, 2026, Veracyte announced that new data from more than 15 studies on its Decipher portfolio will be presented at the 2026 American Urological Association (AUA) Annual Meeting.
On April 28, 2026, JD Health and China Resources Sanjiu (华润三九) launched a community health initiative; a low impact is likely as it is a strategic partnership, scheduled.
On 2026-04-28, Illumina's Board of Directors authorized an additional $1.5 billion for share repurchases; low impact (1-2%) estimated as buybacks typically provide modest price support expected.
Q1 2026 results: revenue +45.1% (RMB 726M), net loss narrowed 91.2%, non-GAAP profit achieved; high importance estimated as significant financial improvement is likely to cause a >10% price impact expected.
Reported strong Q1 2026 financial results on April 27, 2026, with revenue of CNY 12.44 billion (+28.8% YoY) and adjusted non-IFRS net profit of CNY 4.60 billion (+71.7% YoY), beating expectations and causing a significant share price increase.
Asymchem announced its Q1 2026 results on April 27, 2026, reporting a 16.91% YoY revenue increase to RMB 1.802 billion and a 6.82% net profit decrease to RMB 3.04 billion; a 5% price impact is estimated due to mixed results, expected.